Pd-1-pik |
Pd-1-pik |
Phase Ⅰ |
Huashan Hospital of Fudan University |
Glioblastoma multiforme |
Details
|
艾姆地芬 |
|
Phase Ⅰ |
Tianjin Chase Sun Pharmaceutical, Chinese Academy of Medical Sciences |
Solid tumours |
Details
|
RC-98 |
RC-98; RC98 |
Phase Ⅰ |
Remegen |
Solid tumours |
Details
|
Recombinant human anti-PD-L1 monoclonal antibody (Zhaoke Oncology) |
STI-A1014; ZKAB001; STIA-1014 |
Phase Ⅲ |
Zhaoke Oncology |
Osteosarcoma |
Details
|
Recombinant anti-PD-L1 human monoclonal antibody (Jiansu huaiyu) |
|
Phase Ⅰ |
Jiangsu huaiyu pharmaceutical |
Cancer |
Details
|
CA-327 |
CA-327; AUPM-327 |
Preclinical |
Aurigene, Curis |
Cancer |
Details
|
JS-003 |
JS-003,JS003; JS 003 |
Phase Ⅰ |
Shanghai Junshi Biosciences |
Solid tumours |
Details
|
BMS-986189 |
BMS-189; BMS-986189; PD-L1-Milla; BMS-986189-07 |
Phase Ⅰ |
Bristol-Myers Squibb |
Sepsis |
Details
|
MAX-10181 |
MAX-10181 |
Phase Ⅰ |
Maxinovel Pharmaceuticals |
Solid tumours |
Details
|
Bintrafusp alfa |
GSK-4045154; M-7824; MSB-0011359C |
Phase Ⅲ |
Merck Serono, GlaxoSmithKline |
Biliary cancer |
Details
|
Anti-PDL1 chimeric switch receptor modified T-cell therapy (Marino Biotechnology) |
|
Phase Ⅰ |
Marino Biotechnology |
Solid tumours, Glioblastoma |
Details
|
CA-170 |
CA-170; AUPM-170 |
Phase Ⅱ |
Aurigene, Curis |
Cancer |
Details
|
89Zr-durvalumab |
|
Phase Ⅱ |
Radboud University |
Head and neck cancer |
Details
|
KN-046 |
KN-046 |
Phase Ⅲ |
Alphamab |
Non small cell lung cancer (NSCLC) |
Details
|
LY-3434172 |
LY-3434172 |
Phase Ⅰ |
Lilly |
Solid tumours |
Details
|
LOR-S03 |
CDX-527; LOR-A04; LOR-S01; LOR-S03 |
Phase Ⅰ |
Celldex |
Cancer |
Details
|
PD-L1 t-haNK cell therapy |
|
Phase Ⅰ |
NantKwest |
Solid tumours |
Details
|
GNC-038 |
GNC-038 |
IND Filing |
Sichuan Baili Pharmaceutical |
Hematological cancer |
Details
|
Recombinant humanized PD-L1 single domain antibody Fc fusion protein |
KN035;ASC-22;KN-035;ASC22 |
Phase Ⅲ |
Alphamab, 3D Medicines, Ascletis |
Solid tumours, Septic shock, Sepsis, Biliary cancer |
Details
|
CX-072 |
CX-072 |
Phase Ⅱ |
CytomX Therapeutics |
Solid tumours, Lymphoma |
Details
|
SHR-1701 |
SHR-1701,SHR1701; SHR 1701 |
Phase Ⅱ |
Jiangsu Hengrui Medicine |
Lymphoma |
Details
|
BGB-A333 |
BGB-A333,BGBA333 |
Phase Ⅱ |
BeiGene |
Solid tumours |
Details
|
KY-1043 |
KY-1043 |
Preclinical |
Kymab |
Solid tumours |
Details
|
MT-6402 |
MT-6402 |
Preclinical |
Molecular Templates |
Solid tumours |
Details
|
GR-1405 |
GR-1405,GR1405; GR 1405 |
Phase Ⅱ |
Chongqing Genrix Biopharmaceutical, Genrix (Shanghai) Biopharmaceutical |
Nasopharyngeal cancer, Triple negative breast cancer, Squamous cell carcinoma of head and neck cancer (SCCHN), Solid tumours, Lymphoma |
Details
|
Anti PD-L1 monoclonal antibody (Biocad) |
BCD-135 |
Phase Ⅰ |
Biocad |
Solid tumours |
Details
|
Recombinant anti-PD-L1 human monoclonal antibody (Hisun Pharm) |
HS-636 |
Phase Ⅰ |
Hisun Pharm |
Cancer |
Details
|
Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech) |
Z-CTLs |
Phase Ⅰ |
Hunan Zhaotai Yongren Biotech |
Non small cell lung cancer (NSCLC) |
Details
|
IBI-322 |
IBI-322 |
Phase Ⅰ |
Innovent Biologics |
Cancer |
Details
|
Human source and Fc engineered monoclonal antibody (MabSpace) |
MSB-2311,MSB2311 |
Phase Ⅰ |
MabSpace Biosciences |
Solid tumours |
Details
|
Durvalumab/Osimertinib Mesylate |
|
Phase Ⅲ |
MedImmune |
Non small cell lung cancer (NSCLC) |
Details
|
IGV-001 |
IGV-001 |
Phase Ⅰ |
Imvax |
Glioblastoma |
Details
|
FAZ-053 |
FAZ-053,FAZ053 |
Phase Ⅰ |
Novartis, Laekna Therapeutics |
Solid tumours |
Details
|
PD-L1/CTLA4 bispecific monoclonal antibody (Changhai Hospital) |
|
Phase Ⅱ |
Changhai Hospital of Shanghai |
Pancreatic cancer |
Details
|
FS 118 |
FS-118 |
Phase Ⅰ |
F-star, Merck Serono |
hematological malignancies, Solid tumours |
Details
|
Recombinant human anti-PD-L1 monoclonal antibody (Guilin Sanjin) |
|
Phase Ⅰ |
Sanjin Pharmaceutical, Adagene |
Cancer |
Details
|
ES101 |
ES101 |
Phase Ⅰ |
Inhibrx, Elpiscience |
Solid tumours |
Details
|
Cosibelimab |
CK-301; TG-1501 |
Phase Ⅰ |
TG Therapeutics |
Lymphoma, Cancer |
Details
|
BMS-936559 |
BMS-936559; MDX-1105 |
Phase Ⅲ |
Bristol-Myers Squibb |
Non small cell lung cancer (NSCLC) |
Details
|
SHR-1316 |
SHR-1316 |
Phase Ⅲ |
Jiangsu Hengrui Medicine |
Small cell lung cancer (SCLC), Esophagus cancer |
Details
|
ND-021 |
ND-021; NM21-1480 |
Phase Ⅱ |
Numab Therapeutics, CStone Pharmaceuticals |
Advanced solid tumors |
Details
|
Recombinant humanized PD-L1 monoclonal antibody (Taizhou Houde Aoke Technology) |
LP-002 |
Phase Ⅱ |
Taizhou Houde Aoke Technology |
Cutaneous squamous cell carcinoma (CSCC), Solid tumours |
Details
|
IBI318 |
IBI-318 |
Phase Ⅰ |
Innovent Biologics, Lilly |
hematological malignancies, Malignancies |
Details
|
Lodapolimab |
LY-3300054 |
Phase Ⅰ |
Lilly |
Solid tumours |
Details
|
CS-17938 |
CS17938 |
Preclinical |
ChipScreen |
Immunological disorders, Cancer |
Details
|
TQB-2450 |
APL-502; CBT-502; TQ-B2450 |
Phase Ⅲ |
CBT, Chiatai Tianqing (CTTQ) |
Triple negative breast cancer, Non small cell lung cancer (NSCLC), Solid tumours, Liver cancer, Hodgkin lymphoma, Head and neck cancer, Biliary cancer |
Details
|
MCLA-145 |
MCLA-145 |
Phase Ⅰ |
Incyte, Merus |
Solid tumours |
Details
|
KL-A167 |
A-167; HBM-9167; KL-A167 |
Phase Ⅱ |
Sichuan Kelunbotai Biopharmaceutical, Harbour BioMed |
Solid tumours |
Details
|
Y-111 |
Y-111 |
Preclinical |
YZY Bio |
Non small cell lung cancer (NSCLC), Melanoma |
Details
|
KD-045 (Nanjing KAEDI Biotech) |
KD-045 |
Phase Ⅰ |
Nanjing KAEDI Biotech |
Solid tumours |
Details
|
IMC-001 |
IMC-001; STI-3031; STI-A1015 |
Phase Ⅱ |
Sorrento Therapeutics, ImmuneOncia Therapeutics |
Gastrointestinal cancer |
Details
|
Durvalumab/Selumetinib |
|
Phase Ⅰ |
AstraZeneca |
Solid tumours |
Details
|
Durvalumab/Gefitinib |
|
Phase Ⅱ |
MedImmune |
Non small cell lung cancer (NSCLC) |
Details
|
18F-BMS-986192 |
BMS-986192-[18F] |
Phase Not Specified |
Bristol-Myers Squibb |
Cancer |
Details
|
INBRX-105 |
INBRX-105 |
Phase Ⅰ |
Inhibrx |
Solid tumours, Non-Hodgkin's lymphoma (NHL), Hodgkin lymphoma |
Details
|
Recombinant human anti-PDL1 monoclonal antibody (CStone Pharmaceuticals) |
CS-1001; WBP-3155,CS1001 |
Phase Ⅲ |
CStone Pharmaceuticals |
Gastric adenocarcinoma, Non small cell lung cancer (NSCLC), Solid tumours, Lymphoma, Gastroesophageal junction adenocarcinoma, Hodgkin lymphoma |
Details
|
HLX-20 |
HLX-20,HLX20; HLX 20 |
Phase Ⅰ |
Shanghai Henlius Biotech |
Solid tumours |
Details
|
REMD-290 |
REMD-290 |
Preclinical |
REMD Biotherapeutics, Buchang Pharma |
Cancer |
Details
|
CK-301 |
CK-301,CK301 |
Phase Ⅰ |
Dana-Farber Cancer Institute, Checkpoint |
Non small cell lung cancer (NSCLC), Renal cell carcinoma, Merkel cell carcinoma, Urothelial cancer, Mesothelioma, Hodgkin lymphoma, Head and neck cancer, Melanoma |
Details
|
GEN-1046 |
DuoBody-PD-L1x4-1BB; GEN1046; PD-L1x4-1BB |
Phase Ⅱ |
Genmab, BioNTech |
Triple negative breast cancer, Non small cell lung cancer (NSCLC), Endometrial cancer, Urothelial cancer, Squamous cell carcinoma of head and neck cancer (SCCHN), Solid tumours, Cervical carcinoma |
Details
|
c-Met/PD-L1 CAR-T cell (The Second Hospital of Nanjing Medical University) |
|
Phase Ⅰ |
The Second Hospital of Nanjing Medical University |
Primary hepatocellular carcinoma |
Details
|